Who is stepping down from their role at Pfizer?

John D. Young, Group President and Chief Business Officer, has announced his decision to retire.

When will John D. Young's retirement become effective?

Mr. Young will retire in early 2022. He will step down as an executive officer no later than December 31, 2021.

Will John D. Young have any ongoing involvement with Pfizer after his retirement?

Yes, after stepping down as an executive officer, Mr. Young will remain an employee in an advisory role for a period of time in 2022.

What is the significance of this departure for Pfizer investors?

The departure of a Group President and Chief Business Officer signifies a change in key executive leadership. Investors may want to monitor the transition plan and the impact on business strategy and operations.

PFE 8-K: Leadership Changes

Summary

Pfizer Inc. (PFE) has filed an 8-K report announcing the upcoming retirement of John D. Young, Group President and Chief Business Officer, in early 2022. Mr. Young will transition out of his executive officer role by December 31, 2021, and will subsequently serve in an advisory capacity through a portion of 2022. This filing informs investors about a significant leadership change within the company's executive team.

Key Highlights

1John D. Young, Group President and Chief Business Officer, announced his retirement.
2Mr. Young's retirement is scheduled for early 2022.
3He will step down from his executive officer position by December 31, 2021.
4Following his executive role, Mr. Young will remain with Pfizer in an advisory capacity during 2022.
5This change impacts a key leadership position within Pfizer's business operations.

PFIZER INC 8-K Report, Executive Changes (Jul 9, 2021)

Summary

Key Highlights

Frequently Asked Questions